Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01470209 · ClinicalTrials.gov registry record · Phase 1
A Phase I Study of BKM120 and Everolimus in Advanced Solid Malignancies
A Phase 1 study, sponsored by Emory University.
- Completed
- Registry status
- Phase 1
- Development phase
- 43
- Enrollment target
NCT01470209 is a Phase 1 study that has completed, run by Emory University. The registered enrollment target is 43 participants.
The verdict
NCT01470209, a Phase 1 study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 43 participants
- Enrollment target
Study Summary
This study will assess the safety of combining two agents (everolimus and BKM120) for the treatment of advanced cancer arising from solid organ in patients who are no longer benefiting from or unable to withstand standard treatment of these conditions.
Interventions
- DRUG Everolimus
- DRUG BKM120
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2012-01 |
| Est. Completion | 2017-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01470209
The ClinicalTrials.gov registry entry for NCT01470209 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Everolimus is the first listed.
NCT01470209 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01470209 about?
NCT01470209 is a clinical study titled "A Phase I Study of BKM120 and Everolimus in Advanced Solid Malignancies". This study will assess the safety of combining two agents (everolimus and BKM120) for the treatment of advanced cancer arising from solid organ in patients who are no longer benefiting from or unable to withstand standard treatment of these conditions.
What is the current status of trial NCT01470209?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 43 participants. The study started on 2012-01. Estimated completion is 2017-05.
What interventions are being tested in trial NCT01470209?
The interventions under investigation include: Everolimus (DRUG), BKM120 (DRUG).
Who is sponsoring clinical trial NCT01470209?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.